GlassScriptPhysician profile
Dean T Noritake
NPI 1477514495
$11,558.39
in general payments reported to CMS, 2019-2025
37 companies · $4,421 in 2025
The $4,421 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,164 · 2020: $861 · 2022: $306 · 2024: $2,807 · 2025: $4,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,148 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,147.84 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,856.18 | 2019-2025 | Evenity, Tavneos, Enbrel |
| Abbvie INC. | $1,811.06 | 2019-2025 | |
| Pfizer INC. | $1,061.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $746.24 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $727.53 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $696.45 | 2019-2025 | |
| Ucb, INC. | $547.19 | 2019-2025 | Bimzelx |
| Alexion Pharmaceuticals, INC. | $541.07 | 2019-2025 | Strensiq |
| Lilly USA, LLC | $474.06 | 2019-2025 | Zepbound, Taltz |
| Radius Health, INC. | $345.24 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $302.36 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $254.39 | 2024-2025 | Saphnelo |
| Mallinckrodt Enterprises LLC | $225.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $189.52 | 2019-2020 | |
| Genentech USA, INC. | $153.67 | 2019-2025 | Actemra |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Noritake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.